Program
Naltrexone
Also written as “naltrexone implant”, “Naltrexone and Acetaminophen” and “Naltrexone and Acetaminophen-High Dose”.
Its studies are mostly in Obesity · Opioid-Related Disorders · Migraine Disorders · Alcoholism · Depression, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Orexigen Therapeutics | 110 open or running | phase 4since Dec 18, 2015 | Aug 14, 2006 | none ahead |
| Allodynic Therapeutics | 60 open or running | phase 3since Jun 8, 2017 | Feb 17, 2017 | none ahead |
| Shenzhen Sciencare Medical Industries | 42 open or running | phase 3since Feb 8, 2026 | Jun 16, 2023 | Apr 1, 2027phase 3 · NCT07433413 |
| AgelessRx | 31 open or running | phase 3since Dec 18, 2024 | Oct 26, 2020 | none ahead |
| Go Medical Industries Pty | 31 open or running | phase 2since May 16, 2022 | Jan 17, 2019 | Jul 1, 2029phase 2 · NCT05382091 |
| Pfizer | 20 open or running | phase 3since Sep 2, 2011 | Sep 2, 2011 | none ahead |
| Alkermes | 10 open or running | phase 3since Feb 26, 2016 | Feb 26, 2016 | none ahead |
| Annette C. Toledano MD | 10 open or running | phase 2since Aug 11, 2011 | Aug 11, 2011 | none ahead |
| Delpor | 10 open or running | phase 1since Mar 7, 2022 | Mar 7, 2022 | none ahead |
| elite-laboratories-inc | 10 open or running | phase 3since Feb 17, 2015 | Feb 17, 2015 | none ahead |
| pain-therapeutics | 10 open or running | phase 2since Aug 12, 2008 | Aug 12, 2008 | none ahead |
| Takeda | 10 open or running | phase 4since Nov 24, 2015 | Nov 24, 2015 | none ahead |
| the-taub-group | 10 open or running | phase 4since Dec 21, 2017 | Dec 21, 2017 | none ahead |
| Truway Health | 11 open or running | phase 2since Oct 23, 2025 | Oct 23, 2025 | Oct 23, 2034phase 2 · NCT07221565 |
Also a collaborator on its studies: the-emmes-company-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 22 studies since Aug 14, 2006.
- Dec 21, 2017the-taub-group's first study: phase 4 study in DepressionNew to the-taub-groupthe-taub-group · NCT03386448 · 14 enrolled · United States
- Jan 17, 2019Go Medical Industries Pty's first study: phase 1 study in Opioid-Related DisordersNew to Go Medical Industries PtyGo Medical Industries Pty · NCT03810495 · 20 enrolled · United States
- Oct 26, 2020AgelessRx's first studies: 2 phase 2 studies in COVID-19New to AgelessRxAgelessRx · NCT04604704, NCT04604678
- Jan 17, 2021Phase 1 study in Opioid-Related DisordersGo Medical Industries Pty · NCT04716881 · 9 enrolled · United States
- Mar 7, 2022Delpor's first study: phase 1 study in Behavior, AddictiveNew to DelporDelpor · NCT05304364 · 10 enrolled · Australia
- May 16, 2022Phase 2 study in Opioid-Related DisordersGo Medical Industries Pty · NCT05382091 · 250 planned
- Dec 27, 2022Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT05685225 · United States
- Jun 16, 2023Shenzhen Sciencare Medical Industries's first study: phase 1 study in AUDNew to Shenzhen Sciencare Medical IndustriesShenzhen Sciencare Medical Industries · NCT05919017 · 60 planned · China
- Jan 30, 2024Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT06245902 · 92 enrolled · United States
- Dec 18, 2024Phase 3 study in LongevityAgelessRx · NCT07092618 · 150 planned · United States
- Jun 3, 2025Phase 2 study in Opioid-Related DisordersShenzhen Sciencare Medical Industries · NCT07014644 · 31 enrolled · China
- Oct 23, 2025Truway Health's first study: phase 2 study in Lupus Erythematosus, SystemicNew to Truway HealthTruway Health · NCT07221565 · 120 planned · United States
- Dec 30, 2025Phase 2 study in AUDShenzhen Sciencare Medical Industries · NCT07333638 · 210 enrolled · China
- Feb 8, 2026Phase 3 study in AlcoholismPhase 3 reachedShenzhen Sciencare Medical Industries · NCT07433413 · 240 planned
Ahead
- Apr 1, 2027Primary completion: phase 3 study in AlcoholismShenzhen Sciencare Medical Industries · NCT07433413
- Jul 1, 2029Primary completion: phase 2 study in Opioid-Related DisordersGo Medical Industries Pty · NCT05382091
- Oct 23, 2034Primary completion: phase 2 study in Lupus Erythematosus, SystemicTruway Health · NCT07221565
TargetBeta
“Opioid receptors; mu/kappa/delta antagonist; Opioid receptors; mu/kappa/delta antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07433413Alcoholism | 3 | Not yet recruiting | Shenzhen Sciencare Medical Industries | Apr 1, 2027 | 240 |
| NCT07333638AUD · China | 2 | Completed | Shenzhen Sciencare Medical Industries | Sep 27, 2024 | 210 |
| NCT07221565Lupus Erythematosus, Systemic · United States | 2 | By invitation | Truway Health | Oct 23, 2034 | 120 |
| NCT07014644Opioid-Related Disorders · China | 2 | Completed | Shenzhen Sciencare Medical Industries | May 13, 2020 | 31 |
| NCT07092618Longevity · United States | 3 | Recruiting | AgelessRx | Aug 2025 | 150 |
| NCT06245902Migraine Disorders · United States | 2 | Completed | Allodynic Therapeutics | Feb 8, 2018 | 92 |
| NCT05919017AUD · China | 1 | Recruiting | Shenzhen Sciencare Medical Industries | Dec 31, 2023 | 60 |
| NCT05685225Migraine Disorders · United States | 2 | Withdrawn | Allodynic Therapeutics | Dec 2, 2025 | 0 |
| NCT05382091Opioid-Related Disorders | 2 | Not yet recruiting | Go Medical Industries Pty | Jul 1, 2029 | 250 |
| NCT05304364Behavior, Addictive · Australia | 1 | Completed | Delpor | Oct 21, 2022 | 10 |
| NCT04716881Opioid-Related Disorders · United States | 1 | Completed | Go Medical Industries Pty | Apr 4, 2022 | 9 |
| NCT04604704COVID-19 · United States | 2 | Completed | AgelessRx | Jan 23, 2023 | 36 |
| NCT04604678COVID-19 · United States | 2 | Withdrawn | AgelessRx | Aug 2021 | 0 |
| NCT03810495Opioid-Related Disorders · United States | 1 | Completed | Go Medical Industries Pty | Mar 18, 2021 | 20 |
| NCT03386448Depression · United States | 4 | Completed | the-taub-group | Nov 20, 2018 | 14 |
| NCT03201393Radiculopathy · United States | 2 | Completed | Allodynic Therapeutics | Jul 26, 2018 | 12 |
| NCT03194555Headache · United States | 2 | Completed | Allodynic Therapeutics | Jul 26, 2018 | 12 |
| NCT03185143Migraine With and Without Aura · United States | 3 | Completed | Allodynic Therapeutics | May 7, 2018 | 36 |
| NCT03061734Migraine Disorders · United States | 2 | Completed | Allodynic Therapeutics | Feb 8, 2018 | 92 |
| NCT02745912Healthy Subjects | 1 | Completed | Orexigen Therapeutics | Jun 2016 | 30 |
| NCT02735603Heart Repolarization · United States | 1 | Completed | Orexigen Therapeutics | Jul 2016 | 84 |
| NCT02696434Opioid-Related Disorders · United States | 3 | Completed | Alkermes | Nov 2017 | 101 |
| NCT02638129Obesity · United States | 4 | Terminated | Orexigen Therapeutics | Jun 2016 | 67 |
| NCT02616315Weight Regain Post Bariatric Surgery · United States | 4 | Withdrawn | Takeda | Oct 2017 | 0 |
| NCT02391571Substance Withdrawal Syndrome · United States | 3 | Completed | elite-laboratories-inc | Mar 2015 | 26 |
| NCT01825447Healthy · United States | 1 | Completed | Pfizer | Sep 2013 | 89 |
| NCT01428583Chronic Noncancer Pain · United States | 3 | Completed | Pfizer | May 2012 | 395 |
| NCT01415895Back Pain · United States | 2 | Completed | Annette C. Toledano MD | Feb 2013 | 78 |
| NCT00758966Obsessive-Compulsive Disorder · United States | 2 | Terminated | Orexigen Therapeutics | Dec 2008 | 8 |
| NCT00734461Opioid-Related Disorders · United States | 2 | Completed | pain-therapeutics | Mar 2009 | 14 |
| NCT00711477Obesity · United States | 2 | Completed | Orexigen Therapeutics | Jun 2010 | 46 |
| NCT00624858Depression · United States | 2 | Completed | Orexigen Therapeutics | Jul 2009 | 25 |
| NCT00567255Obesity · United States | 3 | Completed | Orexigen Therapeutics | Jun 2009 | 1,496 |
| NCT00532779Obesity · United States | 3 | Completed | Orexigen Therapeutics | May 2009 | 1,742 |
| NCT00474630Obesity · United States | 3 | Completed | Orexigen Therapeutics | Jun 2009 | 505 |
| NCT00456521Obesity · United States | 3 | Completed | Orexigen Therapeutics | Dec 2008 | 793 |
| NCT00364871Obesity · United States | 2 | Completed | Orexigen Therapeutics | Mar 2007 | 410 |
How it is read
Names in the registry
- “Naltrexone”, 5 entries
- “naltrexone implant”, 2 entries
- “Naltrexone and Acetaminophen”, 2 entries
- “Naltrexone and Acetaminophen-High Dose”, 2 entries
- “Naltrexone SR 32 mg/bupropion SR 360 mg/day”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 7 studies
- Opioid-Related Disorders, 6 studies
- Migraine Disorders, 4 studies
- Alcoholism, 2 studies
- Depression, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.